Physician
Prime Pediatrics, LLC
Prime Pediatrics, LLC was paid $3.15M by Medicaid between Jan 2018 and Nov 2024, across 58 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 34% of everything it billed.
33Billing provider infoPRIME PEDIATRICS, LLC
GAITHERSBURG, MD 20878
GAITHERSBURG, MD 20878
33aNPI1316286032assigned 02/01/2013
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$3.15M
24GClaims61,491
24DCodes billed58
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Maryland
Rank by total paid#3 of 54
Median peer was paid$131K
This provider vs. median24×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 264 | $7K | |
| 2019 | 396 | $9K | |
| 2020 | 9,246 | $438K | |
| 2021 | 10,629 | $533K | |
| 2022 | 13,132 | $772K | |
| 2023 | 15,604 | $752K | |
| 2024incomplete | 12,220 | $642K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 8,992 | 7,531 | $1.08M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 7,596 | 6,405 | $665K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.5% | 1,944 | 1,860 | $205K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.7% | 1,705 | 1,652 | $179K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.8% | 893 | 821 | $152K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.7% | 1,562 | 1,355 | $149K |
| 86328 | 3.4% | 2,522 | 2,248 | $108K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.4% | 907 | 873 | $106K |
| 92552 | 2.0% | 2,559 | 2,463 | $63K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.7% | 3,858 | 3,462 | $55K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.6% | 3,929 | 3,434 | $51K |
| 90686 | 1.2% | 1,667 | 1,572 | $37K |
46 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 1,589 | $36K |
| D1206 | Topical application of fluoride varnish | <1% | 1,095 | $26K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,355 | $25K |
| 90648 | <1% | 1,134 | $25K | |
| 90677 | <1% | 120 | $24K | |
| 90670 | <1% | 928 | $21K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 783 | $18K |
| 96127 | <1% | 3,647 | $17K | |
| 90723 | <1% | 712 | $15K | |
| 90633 | <1% | 525 | $12K | |
| 90680 | <1% | 437 | $9K | |
| 94760 | <1% | 3,970 | $9K | |
| 90651 | <1% | 258 | $6K | |
| 0071A | <1% | 145 | $6K | |
| 99173 | <1% | 2,125 | $5K | |
| 0072A | <1% | 124 | $5K | |
| 69210 | <1% | 156 | $5K | |
| 83655 | <1% | 329 | $4K | |
| 90734 | <1% | 145 | $3K | |
| 0002A | <1% | 78 | $3K | |
| 90656 | <1% | 143 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 789 | $3K |
| 0001A | <1% | 68 | $3K | |
| 87807 | <1% | 229 | $3K | |
| 92567 | <1% | 125 | $2K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 81 | $2K |
| 92550 | <1% | 59 | $1K | |
| 0004A | <1% | 32 | $1K | |
| 81003 | <1% | 615 | $1K | |
| 90716 | <1% | 40 | $931.20 | |
| 90715 | <1% | 38 | $861.36 | |
| 96161 | <1% | 335 | $856.30 | |
| 85018 | <1% | 384 | $828.59 | |
| 90685 | <1% | 36 | $768.24 | |
| 90655 | <1% | 34 | $768.24 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 72 | $692.54 |
| 90707 | <1% | 26 | $605.28 | |
| 90710 | <1% | 27 | $605.28 | |
| 90620 | <1% | 27 | $582.00 | |
| 81000 | <1% | 126 | $397.12 | |
| 90696 | <1% | 15 | $325.92 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 86 | $274.96 |
| 97802 | <1% | 44 | $273.27 | |
| 97803 | <1% | 59 | $84.33 | |
| 36416 | <1% | 177 | $30.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAMALI, FARNOUSH (OWNER)